H.R. 5160 House Health
Stem Cell Therapeutic and Research Reauthorization Act of 2025
STAGE 4 OF 8 — HOUSE FLOOR
Currently in the House. Last action: received in the senate. read twice. placed on senate legislative calendar under general orders. calendar no. 464 on Jul 21, 2026.
- House Introduced in House Sep 4, 2025
- House Referred to the House Committee on Energy and Commerce. Sep 4, 2025
- House Referred to the Subcommittee on Health. Sep 4, 2025
- House Subcommittee Consideration and Mark-up Session Held May 13, 2026
- House Forwarded by Subcommittee to Full Committee by Voice Vote. May 13, 2026
- House Committee Consideration and Mark-up Session Held May 21, 2026
- House Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0. May 21, 2026
- House Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724. Jul 2, 2026
- House Placed on the Union Calendar, Calendar No. 629. Jul 2, 2026
- House Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642) Jul 20, 2026
- House Mr. Guthrie moved to suspend the rules and pass the bill, as amended. Jul 20, 2026
- House Considered under suspension of the rules. (consideration: CR H4642-4643) Jul 20, 2026
- House DEBATE - The House proceeded with forty minutes of debate on H.R. 5160. Jul 20, 2026
- House Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. Jul 20, 2026
- House On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642) Jul 20, 2026
- House Motion to reconsider laid on the table Agreed to without objection. Jul 20, 2026
- Senate Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464. Jul 21, 2026
Cosponsors
21
Subjects
Biological and life sciencesBlood and blood diseasesCell biology and embryologyHealth programs administration and fundingOrgan and tissue donation and transplantation
Committees
- Energy and Commerce Committee
- [Reported By, Jul 2, 2026]
- [Markup By, May 21, 2026]
- [Referred To, Sep 4, 2025]
Summary
Stem Cell Therapeutic and Research Reauthorization Act of 2025This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research.Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
[Summary as of: Reported to House]
Comments · 0
Please log in to post a comment.
Loading comments...